Scleroderma — Research Summary
Printed from RareWays (rareways.com.au) on 27 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
The clinical profile of systemic sclerosis without a 'scleroderma pattern' at nailfold capillaroscopy: results from the multicenter SPRING registry of the Italian Society of Rheumatology.
Tonutti Antonio et al. — Journal of translational autoimmunity (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42367240/
- 2.
Injectable platelet-rich fibrin as a valid therapeutic option for inactive linear morphea (en coup de saber): report of cases.
Ai Xuechen et al. — The Journal of dermatological treatment (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41773608/
- 3.
Cardiovascular risk goal attainment in the United States rheumatologic population.
Granstaff Kaitlyn et al. — American journal of preventive cardiology (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42395074/
- 4.
Vulvar findings and sexual dysfunction in women with systemic sclerosis.
Mercipinetti Marine et al. — JAAD international (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42382269/
- 5.
Complete plastome data of rare
Almerekova Shyryn et al. — Data in brief (1 August 2026)
https://pubmed.ncbi.nlm.nih.gov/42293441/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
Recruiting — Phase 2 — GlaxoSmithKline
https://clinicaltrials.gov/study/NCT05878717
- 2.
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
Recruiting — Phase 1 — Nkarta, Inc.
https://clinicaltrials.gov/study/NCT06733935
- 3.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
- 4.
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Recruiting — Phase 2 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT06655896
- 5.
A Study of AZD0120 in Autoimmune Diseases
Recruiting — Phase 1 — AstraZeneca
https://clinicaltrials.gov/study/NCT07295847
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Scleroderma
Scleroderma (systemic sclerosis) is a rare autoimmune connective tissue disease characterised by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. It ranges from limited cutaneous to diffuse forms with major organ involvement. Interstitial lung disease and pulmonary arterial hypertension are leading causes of disease-related mortality.
Most Recent Research
BACKGROUND: Microvascular alterations can be detected with nailfold videocapillaroscopy, useful for systemic sclerosis (SSc) diagnosis upon identification of the "scleroderma pattern" (NVC-SP). However, this pattern is missing in a subset of SSc patients. METHODS: This retrospective analysis on the multicenter Italian SPRING cohort of SSc patients assessed the prevalence and characteristics of patients without NVC-SP. Associations with demographic and clinical features were evaluated using logistic regression (cross-sectional) and mixed-effects models (longitudinal). RESULTS: Out of 1689 SSc patients with available NVC information, 90 (5.3%) did not have the NVC-SP. These patients were older at SSc onset (53 vs. 49 years) and more frequently sine scleroderma (31% vs 12%, p < 0.001). The overall burden of vascular complications was milder in this subset, with a lower prevalence of pitting scars (33% vs 48%), telangiectasias (52% vs 74%), and calcinosis (3.4% vs 12%). During the follow-up, mRSS remained lower (60-month mean 4 vs 7, p = 0.002), as well as the estimated probability of vascular complications. Moreover, despite comparable values at baseline, DLCO remained significantly higher in patients without NVC-SP at the following time points (12, 24, and 60 months, p < 0.05). The presence of "late" NVC-SP was independently associated with ILD (OR 1.83, 95% CI 1.05-3.18). CONCLUSIONS: The absence of NVC-SP in 5.3% of SPRING SSc patients may identify a subset characterized by milder disease, with a lower burden of vascular and organ complications. Conversely, lung involvement was more frequently observed in patients with more severe NVC microangiopathy.
Common Questions
What is Scleroderma?
Scleroderma (systemic sclerosis) is a rare autoimmune connective tissue disease characterised by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. It ranges from limited cutaneous to diffuse forms with major organ involvement. Interstitial lung disease and pulmonary arterial hypertension are leading causes of disease-related mortality.
How many clinical trials are available for Scleroderma?
RareWays currently indexes 562 clinical trials for Scleroderma, of which 158 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Scleroderma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Scleroderma.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.